The study examines the prevalence of lung cancer screening (LCS) in the United States using data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS). The National Lung Screening Trial and subsequent US Preventive Services Task Force (USPSTF) recommendations have led to the implementation of low-dose computed tomography (LCS) for individuals with significant smoking exposure. Despite these recommendations, LCS uptake has been low, with only 21% of eligible individuals screened in 2021. The study compares LCS prevalence in 2022 by sociodemographic characteristics and state, using both 2013 and 2021 USPSTF eligibility criteria. The 2022 LCS-eligible population increased by 65.9% compared to 2013 criteria, with the number of individuals newly eligible under 2021 criteria (20 pack-years [PYs]) also increasing. The 2022 LCS prevalence was 16.4% using 2021 criteria and 19.6% using 2013 criteria, with a significant increase in screening among Asian, Black, Hispanic, and female individuals. The study highlights the need for updated LCS eligibility criteria to reduce disparities and emphasizes the importance of increasing LCS uptake nationwide as a public health priority. The findings suggest that while expanded eligibility criteria may help identify more individuals at risk, the overall screening rates remain low.The study examines the prevalence of lung cancer screening (LCS) in the United States using data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS). The National Lung Screening Trial and subsequent US Preventive Services Task Force (USPSTF) recommendations have led to the implementation of low-dose computed tomography (LCS) for individuals with significant smoking exposure. Despite these recommendations, LCS uptake has been low, with only 21% of eligible individuals screened in 2021. The study compares LCS prevalence in 2022 by sociodemographic characteristics and state, using both 2013 and 2021 USPSTF eligibility criteria. The 2022 LCS-eligible population increased by 65.9% compared to 2013 criteria, with the number of individuals newly eligible under 2021 criteria (20 pack-years [PYs]) also increasing. The 2022 LCS prevalence was 16.4% using 2021 criteria and 19.6% using 2013 criteria, with a significant increase in screening among Asian, Black, Hispanic, and female individuals. The study highlights the need for updated LCS eligibility criteria to reduce disparities and emphasizes the importance of increasing LCS uptake nationwide as a public health priority. The findings suggest that while expanded eligibility criteria may help identify more individuals at risk, the overall screening rates remain low.